@article{1438586,
      recid = {1438586},
      author = {Ling, Silvia Cw. and Trieu, Steven.},
      title = {Resistance to targeted therapies in multiple myeloma /},
      publisher = {Springer,},
      address = {Cham :},
      pages = {1 online resource (161 pages)},
      year = {2021},
      note = {4.5.6 The Bone Marrow Microenvironment.},
      abstract = {Multiple Myeloma remains an incurable malignancy. As the  disease progresses, it invariably becomes resistant to  treatment and almost all patients develop refractory  disease. There are multiple different types of targeted  therapies and many of them are used in combination at  different stages of disease. Targeted therapies that are  approved to be used include Proteasome Inhibitors,  Immunomodulatory Drugs and Monoclonal Antibodies. Second  and third generations of these drugs are developed to  overcome resistance and they have unique mechanism of  actions. Targeted therapies that are undergoing clinical  trials include CAR-T cells, bi-specific antibodies,  vaccines, ubiquitin ligase inhibitors and BCL-2 inhibitors.  This book will help to develop an understanding of targeted  therapies in Multiple Myeloma. Its goal is to provide a  unique review of the mechanism of action and resistance of  the many targeted therapies in Multiple Myeloma by leaders  of the field. The book will be useful for students in  medical science, clinicians, health professionals,  scientists, pharmaceutical professionals, drug developers,  and policy makers. This book will provide an insightful  knowledge of the biology of Multiple Myeloma, the mechanism  of action and resistance of targeted therapies, application  of biomarkers and genomics and possible strategies in  overcoming resistance and future development.},
      url = {http://library.usi.edu/record/1438586},
      doi = {https://doi.org/10.1007/978-3-030-73440-4},
}